Advertisement

Comparative Efficacy and Safety of First - and Second-Generation Antipsychotics in the Treatment of Schizophrenia: Facts and Fiction

Chapter

Abstract

The introduction of chlorpromazine into clinical practice a half-century ago revolutionized the pharmacological treatment of schizophrenia (Nasrallah and Tandon, 2009). Fifty typical or first-generation antipsychotics (FGAs) have since become available around the world (Table 1). These agents are extremely effective in reducing the positive symptoms of schizophrenia (delusions, hallucinations, disorganized thinking, and paranoia) and allowed deinstitutionalization of persons with schizophrenia. These agents are found to be minimally effective, however, against negative and cognitive symptoms that contribute to much of the disability associated with schizophrenic illness. Additionally, they do not substantially diminish the suicidality and social dysfunction associated with the illness. Furthermore, these medications cause a range of adverse effects including acute extrapyramidal symptoms and tardive dyskinesia. To a considerable extent because of their poor tolerability, patients often do not take these medications as prescribed and this, in turn, leads to psychotic relapses and poor outcome.

Keywords

Schizophrenia Patient Tardive Dyskinesia Antipsychotic Agent Antipsychotic Treatment Antipsychotic Effect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry, 2001; 158:518–526.CrossRefPubMedGoogle Scholar
  2. Constantine RJ, Richard SM, Surles RC, et al. Optimizing pharmacotherapy of schizophrenia : tools for the psychiatrist. Curr Psychosis Ther Rep, 2006; 4:5–11.CrossRefGoogle Scholar
  3. Davies LM, Lewis S, Jones PB, et al. Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomized controlled trial in schizophrenia responding poorly to previous therapy. Br J Psychiatry, 2007; 191:14–22.CrossRefPubMedGoogle Scholar
  4. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry, 2003; 60:553–564.CrossRefPubMedGoogle Scholar
  5. Fleischhacker WW, Cetkovich-Bakmas M, De Hert M, Hennekens CH, Lambert M, Leucht S, Maj M, Mclntyre RS, Naber D, Newcomer JW, Olfson M, Osby U, Sartorius N, Lieberman JA. Comorbrid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. Journal of Clinical Psychiatry, 2008; 69(4): 514–519.Google Scholar
  6. Franciosi LP, Kasper S, Garber AJ, et al. Advancing the treatment of people with mental illness: A call to action in the management of metabolic issues. J Clin Psychiatry, 2005; 66:790–798.CrossRefGoogle Scholar
  7. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. British Medical Journal, 2000; 321(7273): 1371–1376.Google Scholar
  8. Heres S, Davis J, Maino K, et al. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry, 2006; 163:185–194.CrossRefPubMedGoogle Scholar
  9. Hugenholtz GW, Heerdink ER, Stolker JJ, et al. Haloperidol dose when used as active comparator in randomized controlled trials with atypical antipsychotics in schizophrenia: comparison with officially recommended doses. J Clin Psychiatry, 2006; 67:897–903.CrossRefPubMedGoogle Scholar
  10. Jibson MD, Tandon R. New atypical antipsychotic medications. J Psychiatr Res, 1998; 32:215–228.CrossRefPubMedGoogle Scholar
  11. Johnsen E, Jørgensen HA. Effectiveness of second generation antipyschotics: a systematic review of randomized trials. BMC Psychiatry, 2008; 8:31.Google Scholar
  12. Jones PB, Davies L, Barnes TR, et al. Randomized controlled trial of effect on quality of life of second-generation versus first generation antipsychotic drugs in schizophrenia. Arch Gen Psychiatry, 2006; 63:1079–1087.CrossRefPubMedGoogle Scholar
  13. Kane JM, Honigfeld G, Singer J, Meltzer HY. Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Arch Gen Psychiatry, 1988; 45:789–796.PubMedGoogle Scholar
  14. Kane JM, Leucht S, Carpenter D, et al. Expert consensus guideline series: optimizing pharmacologic treatment of psychotic disorders. J Clin Psychiatry, 2003; 64(Suppl. 12):1–100.Google Scholar
  15. Kane JM, Meltzer HY, Carson WH, et al. Aripiprazole for treatment-resistant schizophrenia: results of a multi-center, randomized, double-blind, comparison study versus perphenazine. J Clin Psychiatry, 2007; 68:213–223.CrossRefPubMedGoogle Scholar
  16. Kapur S, Remington G. Atypical antipsychotics: New directions and new challenges in the treatment of schizophrenia. Annu Rev Med, 2001; 52:503–517.CrossRefPubMedGoogle Scholar
  17. Keefe RSE, Bilder RM, Davis SM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry, 2007; 64:633–647.CrossRefPubMedGoogle Scholar
  18. Leucht S, Corves C, Arbter D, et al. second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet, 2009; 373:31–41.CrossRefPubMedGoogle Scholar
  19. Lewis S, Lieberman J. CATIE and CUtLASS: can we handle the truth? Br J Psychiatry, 2008; 192:161–163.CrossRefPubMedGoogle Scholar
  20. Lewis SW, Barnes TR, Davies L, et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull, 2006; 32:715–723.CrossRefPubMedGoogle Scholar
  21. Lieberman JA, Stroup ST, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med, 2005; 353:1209–1223.CrossRefPubMedGoogle Scholar
  22. Marder SR, Essock SM, Miller AM, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry, 2004; 161:1334–1349.CrossRefPubMedGoogle Scholar
  23. McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior antipsychotic treatment. Am J Psychiatry, 2006; 163:600–610.CrossRefPubMedGoogle Scholar
  24. Meltzer HY. What’s atypical about atypical antipsychotic drugs? Curr Opin Pharmacol, 2004; 4:53–57.CrossRefPubMedGoogle Scholar
  25. Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry, 2003; 60:82–91.CrossRefPubMedGoogle Scholar
  26. Meltzer HY, Bobo WV. Interpreting the efficacy findings in the CATIE study: what the clinician should know. CNS Spectrums, 2006; 11(Suppl. 7):14–24.PubMedGoogle Scholar
  27. Miller AL, Hall CS, Buchanan RW, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry, 2004; 65:500–508.CrossRefPubMedGoogle Scholar
  28. Miller DD, Caroff SN, Davis SM, et al. Extrapyramidal side-effects of antipsychotics in a randomized trial. Br J Psychiatry, 2008; 193:279–288.CrossRefPubMedGoogle Scholar
  29. Moller H-J. Definition, psychopharmacological basis and clinical evaluation of novel/atypical neuroleptics: methodological issues and clinical consequences. World J Biol Psychiatry, 2000; 1:75–91.CrossRefPubMedGoogle Scholar
  30. Moller H-J. Are the new antipsychotics no better than the classical neuroleptics? The problematic answer from the CATIE study. Eur Arch Psychiatry Clin Neurosci, 2005; 255:371–372CrossRefPubMedGoogle Scholar
  31. Montgomery JH, Byerly M, Carmody T, et al. An analysis of the effect of funding source in randomized clinical trials of second-generation antipsychotics for the treatment of schizophrenia. Control Clin Trials, 2004; 25:598–612.CrossRefPubMedGoogle Scholar
  32. Nasrallah HA, Tandon R: Conventional antipsychotics. In Nemeroff C, Schatzberg A (eds) American Psychiatric Press Textbook of Psychopharmacology, 4th Edition, American Psychiatric Press, Washington DC, 2009.Google Scholar
  33. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs, 2005; 19(Suppl. 1):1–93.PubMedGoogle Scholar
  34. Rosenheck RA, Leslie DL, Sindelar J, et al. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry, 2006; 163:2080–2089.CrossRefPubMedGoogle Scholar
  35. Sikich L, Frazier JA, McClellan J, et al. Double-blind comparison of first- and second- generation antipsychotics in early-onset schizophrenia and schizoaffective disorder: Findings from the treatment of early-onset schizophrenia study (TEOSS). Am J Psychiatry, 2008; 165:1420–1431.CrossRefPubMedGoogle Scholar
  36. Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry, 2006; 163:611–622.CrossRefPubMedGoogle Scholar
  37. Swartz MS, Perkins DO, Stroup ST, et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am J Psychiatry, 2007; 164:428–436.CrossRefPubMedGoogle Scholar
  38. Tandon R, Belmaker RH, Gattaz WF, et al. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res, 2008; 100:20–38.CrossRefPubMedGoogle Scholar
  39. Tandon R, Carpenter WT, Davis JM. First- and second-generation antipsychotics: Learning from CUtLASS and CATIE. Arch Gen Psychiatry, 2007; 64:977–978.CrossRefPubMedGoogle Scholar
  40. Tandon R, Fleischhacker WW. Comparative efficacy of antipsychotics in the treatment of schizophrenia: A critical assessment. Schizophr Res, 2005; 79:145–155.CrossRefPubMedGoogle Scholar
  41. Tandon R, Nasrallah HA. Subjecting meta-analyses to closer scrutiny: little support for differential efficacy among second-generation antipsychotics. The authors reply. Arch Gen Psychiatry, 2006; 63:935–939.CrossRefPubMedGoogle Scholar
  42. Tandon R, Targum SD, Nasrallah HA, Ross R. Strategies for maximizing clinical effectiveness in the treatment of schizophrenia. J Psychiatr Pract; 2006 12:348–363.CrossRefPubMedGoogle Scholar
  43. Tuunainen A, Wahlbeck K, Gilbody SM. Newer atypical antipsychotic medication in comparison to clozapine: a systematic review of randomized trials. Schizophr Res, 2002; 56:1–10.CrossRefPubMedGoogle Scholar
  44. Weiden PJ. EPS profiles: the atypical antipsychotics are not all the same. Journal of Psychiatric Practice, 2007; 13(1): 13–24.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.University of Florida Medical SchoolGainesvilleUSA

Personalised recommendations